


DOCKET NO.: CELL-0072

1625 15
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

John Robert Porter, Et Al.

Serial No.: 09/326,020

Filing Date: June 4, 1999

For: Phenylalanine Derivatives

Confirmation No.: 3600

Group Art Unit: 1625

Examiner: B.M. Robinson

#34
A. H. H. H.
1/16/03

DATE OF DEPOSIT: December 17, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, DC 20231.

Jane E. Inglese

TYPED NAME: Jane E. Inglese
REGISTRATION NO.: 48,444

Box ☐ NON-FEE
☐ AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

REPLY TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ An Amendment Responsive to the Office Action Dated August 19, 2002.
- ☐ An Amendment Supplemental to the Paper filed
- ☐ Other:

12/26/2002 SMINASS1 00000035 09326020

01 FC:1251

110.00 OP

- ☐ Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.
- ☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:
- ☐ an Independent Inventor
- ☐ a Small Business Concern
- ☐ a Nonprofit Organization
- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.
- ☐ Loss of Entitlement Enclosed
- ☐ Substitute Pages of the Specification are enclosed.
- ☐ An Abstract is enclosed.
- ☐ Sheets of Proposed Corrected Drawings are enclosed.
- ☐ A Certified Copy of each of the following applications: is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☒ Appended Material as follows: Appendix A, Drug Report from the Investigational Drugs Database "Natalizumab" (5 pages); Appendix B, Bochner, Bruce S. "Targeting VLA-4 Intergrin Function: Potential Therapeutic Implications" pgs. 113-147.
- ☐ Other Material as follows:

FEE CALCULATION

☐ No Additional Fee is Due.


				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	16	20 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$0
INDEP. CLAIMS	3	3 (3 MINIMUM)	0	\$42 EACH	\$	\$84 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$0
<input checked="" type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$110.00
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$0
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$0
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$0
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$0
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$0
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							\$0
TOTAL FEE DUE					\$		\$110.00

- ☒ A check in the amount of **\$110.00** is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- ☒ Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response to the Office Action of August 19, 2002 to and through December 17, 2002 comprising an extension of the shortened statutory period of one (1) month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.
- ☐ The foregoing amount due for filing this paper.

- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.
- ☒ Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: December 17, 2002



Jane E. Inglese
Registration No. 48,444

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



CELL-0072

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John Robert Porter, et al.

Serial No.: 09/326,020

Group Art Unit: 1625

Filed: June 4, 1999

Examiner: Binta Robinson

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

For: **PHENYLALANINE DERIVATIVES**

I, Jane E. Inglese, Registration No. 48,444 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On December 17, 2002

Jane Inglese
Jane E. Inglese, Registration No. 48,444

Assistant Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR RECONSIDERATION

In response to the Office Action issued August 19, 2002, Applicants respectfully request entry of the following amendments, without prejudice.

In the Claims:

Please amend claims 1, 14, and 18 to read as follows.

1. (Amended Four Times) A compound of formula (1a):

[Handwritten signature]